FIELD: chemical engineering.
SUBSTANCE: invention relates to a compound represented by the structural formula (I) ({5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-6-aminopyridazin -3-yl}-N-{4-[((3S,5R)-3,5-dimethylpiperazinyl)carbonyl]phenyl}carboxamide hydrochloride) and its novel crystalline form of a dihydrate and a trihydrate as well as a method for producing a compound and a crystalline form corresponding to intermediate compounds, a pharmaceutical composition containing a compound according to the invention, use for preparing a pharmaceutical product for the treatment of a disease, disorder or condition in a patient where the disease, disorder or condition is associated with c-Met, CSF1R, ROS1 or a fused protein based on ROS1, TRKA or a fused protein based on TRKA, TRKB, TRKC, ALK, ALKATI or a fused protein based on ALK.
EFFECT: technical result: obtained are novel crystalline forms of the compound of formula (I) showing better solubility and higher suction.
35 cl, 12 dwg, 32 tbl, 14 ex
